Rebamipide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rebamipide
Accession Number
DB11656
Type
Small Molecule
Groups
Investigational
Description

Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
OPC-12759
Categories
UNII
LR583V32ZR
CAS number
90098-04-7
Weight
Average: 370.79
Monoisotopic: 370.0720347
Chemical Formula
C19H15ClN2O4
InChI Key
ALLWOAVDORUJLA-UHFFFAOYSA-N
InChI
InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
IUPAC Name
2-[(4-chlorophenyl)formamido]-3-(2-hydroxyquinolin-4-yl)propanoic acid
SMILES
OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5042
PubChem Substance
347828027
ChemSpider
4866
ChEBI
93814
ChEMBL
CHEMBL1697771
Wikipedia
Rebamipide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherHealthy Male Volunteers1
1CompletedTreatmentDry Eye Syndromes1
1CompletedTreatmentHealthy Volunteers1
2CompletedPreventionDry Eye Syndromes1
2CompletedTreatmentDry Eye Syndromes1
2CompletedTreatmentDry Eye Syndromes / Keratoconjunctivitis Sicca1
2CompletedTreatmentEye Dryness / Keratoconjunctivitis Sicca1
2CompletedTreatmentGastritis1
2CompletedTreatmentKeratoconjunctival Epithelial Disorder1
2CompletedTreatmentSjögren's Syndrome / Xerostomia1
2CompletedTreatmentUlcerative Colitis (UC)1
3CompletedPreventionAnkylosing Spondylitis (AS) / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedTreatmentDry Eye Syndrome (DES)1
3CompletedTreatmentDry Eye Syndromes2
3CompletedTreatmentEye Dryness1
3CompletedTreatmentGastric Ulcer (GU)1
3CompletedTreatmentGastritis Chronic / Indigestion1
3CompletedTreatmentKeratoconjunctivitis Sicca2
3Unknown StatusTreatmentGastritis Acute / Gastritis Chronic1
4CompletedTreatmentDry Eye Syndromes / Sjögren's Syndrome1
4CompletedTreatmentGastric Ulcer (GU)2
4CompletedTreatmentGastritis1
4CompletedTreatmentNSAID Induced Gastropathy1
4CompletedTreatmentReflux, Gastroesophageal1
4RecruitingTreatmentIndigestion1
Not AvailableCompletedTreatmentGastric Ulcer (GU)1
Not AvailableUnknown StatusTreatmentGastric Adenoma and Early Gastric Cancer1
Not AvailableUnknown StatusTreatmentImproving Symptoms of Dry Mouth in Sjőgren's Syndrome1
Not AvailableUnknown StatusTreatmentNSAIDs-induced Small-intestinal Injuries1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00766 mg/mLALOGPS
logP3.87ALOGPS
logP3.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.52ChemAxon
pKa (Strongest Basic)1.74ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area99.52 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity96.25 m3·mol-1ChemAxon
Polarizability36.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00xr-0698000000-68b14bd14b18bae9a8c5

Taxonomy

Description
This compound belongs to the class of organic compounds known as hippuric acids. These are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Hippuric acids
Alternative Parents
N-acyl-alpha amino acids / Quinolones and derivatives / Hydroxyquinolines / 4-halobenzoic acids and derivatives / Benzoyl derivatives / Hydroxypyridines / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
N-acyl-alpha amino acid or derivatives / N-acyl-alpha-amino acid / Hippuric acid / Hydroxyquinoline / Quinolone / Alpha-amino acid or derivatives / Halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Quinoline / Benzoyl
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:37 / Updated on November 02, 2018 07:13